Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 28, 2021updated 27 Oct 2021 1:54pm

LoA Update: Jiangsu Hengrui Medicine’s asset SHR-1020 for bile duct cancer plummets 9 points after withdrawn Phase II

Jiangsu Hengrui Medicine’s SHR-1020 (famitinib)for bile duct cancer saw its Phase Transition Success Rate (PTSR) tank nine points to 25% after withdrawing its Phase II.

Jiangsu Hengrui Medicine’s SHR-1020 (famitinib) for bile duct cancer saw its Phase Transition Success Rate (PTSR) tank nine points to 25% after withdrawing its Phase II. The PTSR score change occurred on 23 June after updated the trial from “not yet recruiting” to “withdrawn” on 16 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

The Phase II (NCT04479904) withdrew due to difficulty screening subjects, according to It was originally intended to recruit 37 patients with intrahepatic cholangiocarcinoma patients with fibroblast growth factor receptor2 (FGFR2) genetic aberrations who had failed first-line therapy, as part of an open-label study.

The withdrawn Phase II also generated a 2-point drop in the drug’s Likelihood of Approval (LoA), which fell to 8%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Jiangsu Hengrui has a market cap of $455.18bn.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy